Back to Search Start Over

COUNTERPOINT Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i

Authors :
Seymour, JF
Seymour, JF
Publication Year :
2022

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1340019703
Document Type :
Electronic Resource

Tools

Authors Abstract Subjects Details